⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33775 | 0.71 | — | — | |
| SCHEMBL5789969 | 0.69 | MAPT (0.46) | — | |
| SCHEMBL12561452 | 0.69 | TSHR (0.39) | — | |
| SCHEMBL20558113 | 0.67 | — | — | |
| SCHEMBL15658135 | 0.67 | LMNA (0.42) | — | |
| SCHEMBL15658258 | 0.67 | MAPT (0.44) | — | |
| SCHEMBL1248250 | 0.67 | — | — | |
| SCHEMBL21774218 | 0.67 | — | — | |
| SCHEMBL22125849 | 0.67 | — | — | |
| SCHEMBL6155854 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | claimed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | claimed |
| EP-2755652-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | Novartis AG (CH) | 2014-07-23 | — | — | EP | claimed |
| CN-103930109-A | N-substituted heterocyclyl carboxamides | NOVARTIS AG | 2014-07-16 | — | — | CN | claimed |
| WO-2013038390-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | claimed |
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260049086-A1 | CDK9 INHIBITORS | BAERENKRAFT THERAPEUTICS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12275738-B2 | CDK9 inhibitors | Biolexis Therapeutics, Inc. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4504708-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119137102-A | CDK9 inhibitors | 拜奥列司治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-7629294-B2 | Pyrazolopyrimidines | BAYER CROPSCIENCE LP (DE) | 2009-12-08 | — | — | US | disclosed |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
| US-20080300263-A1 | Pyrazolo [1,5-a] pyrimidine compounds and pharmaceutical compositions containing them | EIRX THERAPEUTICS PLC (IE) | 2008-12-04 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080070893-A1 | Protein Kinase Inhibitors | POLARIS GROUP (CN) | 2008-03-20 | — | — | US | disclosed |
| WO-2007025284-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |